Issue #3: Arranon
Added February 6, 2006 to the
Drug Monographs
Nelarabine (ArraAnonŽ)
Manufacturer: GlaxoSmithKline
Labeled FDA Approved Indications: Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted.
Manufacturer: GlaxoSmithKline
Labeled FDA Approved Indications: Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted.